Celebrex Premedication in Teeth With Symptomatic Irreversible Pulpitis

Effect of Celebrex Pre-medication on the Intra and Post-treatment Endodontic Pain in Teeth With Symptomatic Irreversible Pulpitis: Double Blind Randomized Clinical Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03339544

Enrollment

Registered

2017-11-13

Start date

2017-12-01

Completion date

2019-12-31

Last updated

2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulpitis

Brief summary

Assessing the efficacy of Celebrex premedication on pain during and after endodontic treatment in teeth with symptomatic irreversible pulpits

Detailed description

Owing to the painful nature of endodotnic treatment in teeth with irreversible pulpits, administration of an analgesic and anti-inflammatory could help to lessen the perception of pain, hence decreasing the patient apprehension. Previous clinical trials have shown that the use of NSAIDS as a premedication prior to endodontic treatment was effective in reducing the pain and increasing the anesthetic success, since as high as 80% of the patients with pre-operative pain experience pain after endodontic treatment. In this study, Celebrex (Celecoxib) 200mg will be given to the patients 1 hour before initiation of the treatment, and its effect on reducing the pain will be compared with a placebo. Celebrex being a selective COX-2 inhibitor, it will spare the physiological tissue prostaglandin production while inhibiting the inflammatory prostaglandin production thus allow for effective analgesia with fewer side effects than Non-Selective NSAIDS (nsNSAIDS).

Interventions

DRUGCelebrex premedication

celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.

DRUGPlacebo

placebo is given as a tablet before initiation of endodontic treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Medically free patients * Patients able to understand Visual Analogue Scale and sign the informed conset Mandibular molar teeth with: * Preoperative sharp pain * Vital pulp tissue * Normal peripaical radiographic appearance or slight widening of the lamina dura

Exclusion criteria

* Patients allergic to NSAIDS * Pregnant females * Patients having significant systemic disorder * Patients with psychological disturbances * Patients with bruxism or clenching Teeth that have: * Associated with swelling or fistulous tract * Acute or chronic periapical abscess * Greater than grade I mobility * Periodontitis * No possible restorability * previous endodontic treatment

Design outcomes

Primary

Measure	Time frame	Description
pain intensity (intra-operative pain)	1 hour after administration of the drug up to 2 hours till the end of endodontic treatment	pain intensity during endodontic treatment, measured by Visual Analogue Scale (pain scale)

Secondary

Measure	Time frame	Description
alleviation of pain severity	24 hours	severity of pain is measured by Visual Analogue Scale
number of analgesic tablets taken by the patient after endodontic treatment	24 hours	counting the number of analgesic tablets taken by the patient after the treatment

Contacts

Primary ContactYousra Khaled

yousra.aly28@gmail.com+201003040660

Backup ContactGeraldine Ahmed

geraldineahmed@gmail.com+201226322227

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026